420 Participants Needed

Cemiplimab + Surgery for Advanced Skin Cancer

Recruiting at 111 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: National Cancer Institute (NCI)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on medications for an active infection or certain autoimmune diseases, you may not be eligible to participate.

Is cemiplimab safe for use in humans?

Cemiplimab has been shown to be generally safe and well-tolerated in most patients with advanced cutaneous squamous cell carcinoma, with common side effects including fatigue, diarrhea, itching, and rash. Severe side effects, which are less common, can include inflammation of the lungs, heart, muscles, and liver, and the risk of treatment-related death is about 3% in clinical trials.12345

How does the drug cemiplimab differ from other treatments for advanced skin cancer?

Cemiplimab is unique because it is a monoclonal antibody that targets the PD-1/PD-L1 pathway, which helps the immune system attack cancer cells. It is specifically approved for advanced cutaneous squamous cell carcinoma when surgery or radiation isn't an option, and it has shown better survival rates compared to other systemic treatments like EGFR inhibitors and chemotherapy.12456

What data supports the effectiveness of the drug cemiplimab for advanced skin cancer?

Research shows that cemiplimab, when used before surgery, led to complete responses in 51% of patients with advanced skin cancer. It also improved survival rates compared to other treatments, making it a promising option for patients with advanced cutaneous squamous cell carcinoma.25678

Who Is on the Research Team?

ND

Neil D Gross

Principal Investigator

NRG Oncology

Are You a Good Fit for This Trial?

This trial is for patients with stage III/IV resectable squamous cell skin cancer, either previously untreated or recurrent. Eligible participants must have a confirmed diagnosis of invasive cutaneous squamous cell carcinoma (CSCC) or related metastasis and be able to undergo surgery with curative intent. Mucosal SCC and tumors that are not resectable or involve the skull base are excluded.

Inclusion Criteria

I do not have squamous cell carcinoma in mucosal areas.
My tumor can be surgically removed with the goal of curing me.
My skin cancer is confirmed to be squamous cell carcinoma.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients receive cemiplimab intravenously every 21 days for up to 4 cycles, followed by response-adaptive surgery and optional radiation therapy

12-18 weeks
4 visits (in-person) for cemiplimab, surgery visit, and potential radiation visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 6 years
Follow-up visits at 1, 6, and 12 months post-surgery, then every 3 months for 2 years, every 6 months in year 3, and annually thereafter

What Are the Treatments Tested in This Trial?

Interventions

  • Cemiplimab
  • Surgical Procedure
Trial Overview The study is evaluating if adding Cemiplimab, an immunotherapy drug, to standard treatment (surgery with/without radiation) improves outcomes in treating advanced skin cancer compared to standard treatment alone. The focus is on whether this combination can better help the immune system attack the cancer.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 2 (cemiplimab, surgery, radiation)Experimental Treatment9 Interventions
Group II: Arm 1 (surgery, radiation)Active Control8 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

In a study of 79 patients with resectable stage II-IV cutaneous squamous cell carcinoma, neoadjuvant cemiplimab treatment resulted in a high 12-month event-free survival rate of 89% and a disease-free survival rate of 92%, indicating its efficacy as a pre-surgical treatment option.
The treatment was generally safe, with only 25% of patients receiving adjuvant cemiplimab experiencing grade 3 adverse events, and no grade 4 adverse events or treatment-related deaths reported, suggesting a favorable safety profile.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.Gross, ND., Miller, DM., Khushalani, NI., et al.[2023]
Cemiplimab, a PD-1 inhibitor, shows significant improvements in overall survival (OS) and progression-free survival (PFS) compared to EGFR inhibitors and pembrolizumab, with hazard ratios indicating a strong benefit.
In comparison to platinum-based chemotherapy, cemiplimab also demonstrated superior efficacy in improving overall survival for patients with advanced cutaneous squamous cell carcinoma.
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.Keeping, S., Xu, Y., Chen, CI., et al.[2021]
Cemiplimab demonstrated a significant objective response rate of 46.1% in patients with advanced cutaneous squamous cell carcinoma (CSCC), with complete response rates of 20.3% for metastatic CSCC and 12.8% for locally advanced CSCC, indicating its efficacy as a treatment option.
Patients experienced durable improvements in quality of life and pain control, with significant enhancements observed as early as the second treatment cycle, highlighting the treatment's positive impact on overall well-being.
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.Rischin, D., Khushalani, NI., Schmults, CD., et al.[2022]

Citations

Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. [2023]
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. [2021]
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. [2022]
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. [2021]
Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives. [2023]
Cemiplimab in advanced cutaneous squamous cell carcinoma. [2022]
The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies. [2022]
Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security